Adobe PDF of News Release
CAMBRIDGE, Mass., Apr 27, 2005 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) will hold a
live webcast of its quarterly conference call at 8:30 a.m. (ET) on
Wednesday, May 4, 2005. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. Senior management will discuss
the Company's first-quarter financial results for 2005, progress
towards 2005 goals including the designation of AP23573 as a
fast-track product by the FDA, and additional corporate activities.
The Company will announce the highlights of these topics in a press
release to be issued before the market opens on May 4, 2005 prior to
the conference call.
The live webcast can be accessed by visiting the investor
relations section of the Company's website at
http://ariad.com/investor. The call can be accessed by dialing
866-800-8649 (domestic) or 617-614-2703 (international) five minutes
prior to the start time and providing the passcode 12991095. A replay
of the call will be available on the ARIAD website approximately two
hours after completion of the call and will be archived for two weeks.
About ARIAD
ARIAD is engaged in the discovery and development of breakthrough
medicines to treat disease by regulating cell signaling with small
molecules. The Company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. Medinol Ltd. also is developing stents and other medical
devices that deliver ARIAD's lead cancer product candidate to prevent
reblockage at sites of vascular injury following stent-assisted
angioplasty. ARIAD has an exclusive license to pioneering technology
and patents related to certain NF-(kappa)B treatment methods, and the
discovery and development of drugs to regulate NF-(kappa)B
cell-signaling activity, which may be useful in treating certain
diseases. Additional information about ARIAD can be found on the web
at http://www.ariad.com.
Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company's ability to
accurately estimate the timing and actual research and development
expenses and other costs associated with the preclinical and clinical
development and manufacture of our product candidates, the adequacy of
our capital resources and the availability of additional funding,
risks and uncertainties regarding our ability to manufacture our
product candidates on a commercial scale or to supply our product
candidates to our collaborator for use in its product candidates,
risks and uncertainties regarding our and our collaborator's ability
to successfully enroll and conduct preclinical and clinical studies of
product candidates, including our product candidates to treat cancers
described in this release and our collaborator's medical device
product candidates to treat vascular disease, risks and uncertainties
that clinical trial results at any phase of development including
those described in this release may be adverse or may not be
predictive of future results or lead to regulatory approval of any of
our or our collaborator's product candidates, risks and uncertainties
of third-party intellectual property claims relating to our and our
collaborator's product candidates, and risks and uncertainties
relating to regulatory oversight, the timing, scope, cost and outcome
of legal proceedings, including litigation concerning our NF-(kappa)B
patent portfolio, future capital needs, key employees, dependence on
our collaborators and manufacturers, markets, economic conditions,
products, services, prices, reimbursement rates, competition and other
risks detailed in the Company's public filings with the Securities and
Exchange Commission, including ARIAD's Annual Report on Form 10-K for
the fiscal year ended December 31, 2004. The information contained in
this document is believed to be current as of the date of original
issue. The Company does not intend to update any of the
forward-looking statements after the date of this document to conform
these statements to actual results or to changes in the Company's
expectations, except as required by law.
SOURCE: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
Tom Pearson (Investors)
617-621-2345
or
Pure Communications
Andrea Johnston (Media)
910-681-1088
